Avantor shares drop as Q2 earnings miss expectations despite revenue beat

Published 01/08/2025, 11:22
 Avantor shares drop as Q2 earnings miss expectations despite revenue beat

Investing.com -- Avantor, Inc. (NYSE:AVTR) shares fell 3.05% on Friday after the life sciences tools company reported second quarter adjusted earnings that missed analyst expectations, despite slightly exceeding revenue forecasts.

The company reported adjusted earnings per share of $0.24 for the second quarter, falling short of the $0.25 analyst consensus.

Revenue came in at $1.68 billion, marginally above the $1.67 billion estimate, but still representing a 1% decrease compared to the same period last year. On an organic basis, revenue was flat year-over-year.

Avantor’s second quarter net income declined to $64.7 million from $92.9 million in the prior-year period, with net income margin at 3.8%. Adjusted EBITDA was $279.8 million with a margin of 16.6%, while adjusted operating income reached $252.2 million with a 15% margin.

"In the second quarter, we remained focused on driving growth, enhancing operating leverage, and executing with discipline," said Michael Stubblefield, President and Chief Executive Officer, who will be stepping down from his role on August 18.

By segment, Laboratory Solutions reported net sales of $1.12 billion, a 3% decrease (1% decline organically), while Bioscience Production saw net sales increase 3% to $561.3 million (2% growth organically).

The company generated operating cash flow of $154.4 million and free cash flow of $125.4 million during the quarter. Adjusted net leverage stood at 3.2x as of June 30, 2025.

Avantor previously announced that Emmanuel Ligner will succeed Stubblefield as President and CEO effective August 18, 2025.

Stubblefield noted that despite challenges, "Avantor’s resilient business model, diversified portfolio, and long-standing customer relationships, coupled with our focus on operational excellence, position us to navigate near-term challenges and deliver long-term shareholder value."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.